CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company focused on the discovery and development of novel antibody-based immunotherapies to help the immune system fight cancer and other diseases, today announced that Arthur H. Tinkelenberg, Ph.D., Enumeral’s President and Chief Executive Officer, will present at the 3rd Annual Jefferies Immuno-Oncology Summit at 3:25 pm Eastern Time in the North Atlantic Room of the Boston Harbor Hotel on Thursday, April 7, 2016. The Summit is being held at the Boston Harbor Hotel, Boston Massachusetts, on April 7-8, 2016.
